Jerusalem Pharmaceuticals Co. Ltd. (PEX:JPH)

Jerusalem Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	11.25	12.22	11.74	6.59	7.73	5.44
Short-Term Investments	-	-	-	0.05	0.03	0.03
Trading Asset Securities	-	-	-	-	0.03	0.03
Cash & Short-Term Investments	11.25	12.22	11.74	6.64	7.79	5.49
Cash Growth	-24.58%	4.05%	76.87%	-14.72%	41.69%	171.63%
Accounts Receivable	41.29	37.35	28.25	29.95	31.63	30.81
Other Receivables	-	0.04	-	0	-	-
Receivables	41.29	37.39	28.25	29.95	31.63	30.81
Inventory	13.82	13.45	8.34	10.41	10.88	14.76
Prepaid Expenses	-	0.35	0.31	0.51	0.4	0.73
Other Current Assets	3.15	2.38	2.89	3.1	2.22	3.33
Total Current Assets	69.51	65.79	51.54	50.61	52.91	55.12
Property, Plant & Equipment	30.4	28.77	25.9	27.13	25.48	27.47
Long-Term Investments	14.35	14.23	7.24	6.42	3.22	0.7
Other Intangible Assets	3.37	2.67	1.8	1.55	1.52	3.04
Long-Term Deferred Tax Assets	0.61	0.53	0.4	0.28	0.27	0.2
Other Long-Term Assets	2.77	2.6	2.27	0.32	0.32	0.37
Total Assets	121.02	114.59	89.15	86.32	83.72	86.89

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	9.49	7.89	3.69	3.48	6.56	5.11
Accrued Expenses	-	4	3.58	2.33	1.32	1.99
Short-Term Debt	-	-	0.46	0.52	0.65	0.78
Current Portion of Long-Term Debt	0.94	0.72	0.61	1.13	0.69	0.57
Current Portion of Leases	0.42	0.4	0.3	0.48	0.36	0.55
Current Income Taxes Payable	2.3	3.67	1.29	2.42	2.67	1.66
Other Current Liabilities	7.21	2.61	2.07	1.95	1.46	2.3
Total Current Liabilities	20.36	19.3	12	12.32	13.7	12.97
Long-Term Leases	0.24	0.21	0.14	0.33	0.49	0.72
Long-Term Unearned Revenue	0.54	0.52	0.29	-	-	-
Pension & Post-Retirement Benefits	6.99	6.36	5.12	4.79	4.3	4.64
Total Liabilities	28.13	26.39	17.55	17.44	18.49	18.32

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	36	18	18	18	18	18
Additional Paid-In Capital	3.72	3.72	3.72	3.72	3.72	3.72
Retained Earnings	34.49	51.58	42.83	39.6	34.9	29.89
Comprehensive Income & Other	17.52	13.82	6.04	6.52	7.65	14.87
Total Common Equity	91.73	87.11	70.6	67.84	64.27	66.47
Minority Interest	1.16	1.08	1.01	1.04	0.96	2.1
Shareholders' Equity	92.89	88.2	71.61	68.88	65.23	68.57
Total Liabilities & Equity	121.02	114.59	89.15	86.32	83.72	86.89

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.6	1.32	1.51	2.47	2.18	2.63
Net Cash (Debt)	9.65	10.9	10.23	4.17	5.6	2.86
Net Cash Growth	-30.59%	6.53%	145.52%	-25.64%	95.69%	-
Net Cash Per Share	0.27	0.30	0.28	0.12	0.16	0.08
Filing Date Shares Outstanding	36.01	36	36	36	36	36
Total Common Shares Outstanding	36.01	36	36	36	36	36
Working Capital	49.15	46.49	39.53	38.28	39.2	42.16
Book Value Per Share	2.55	2.42	1.96	1.88	1.79	1.85
Tangible Book Value	88.36	84.44	68.8	66.29	62.75	63.43
Tangible Book Value Per Share	2.45	2.35	1.91	1.84	1.74	1.76
Land	-	10.43	9.49	10.63	9.24	8.31
Buildings	-	16.73	15.42	15.64	15.73	16.34
Machinery	-	35.71	30.8	29.47	28.78	31.82
Construction In Progress	-	0.01	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error